文献速递认知障碍与痴呆

双种族队列中阿尔茨海默病血浆生物标志物与认知及医学共病的关联

Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.
PubMed 文献 · Neurology · 2023-08-14

在梅奥诊所杰克逊维尔阿尔茨海默病研究中心评估的267名非裔美国人与268名非西班牙裔白人参与者中,按年龄、性别和认知状态匹配后,血浆AD生物标志物水平在两组间无差异;性别差异、慢性肾病和血管危险因素而非自报种族贡献了血浆AD生物标志物的变异。

要点

  • 非裔美国人与非西班牙裔白人之间血浆AD生物标志物水平无差异。
  • 女性参与者GFAP较高(177.5 pg/mL vs 157.73 pg/mL;p=0.002),p-tau181较低(2.62 pg/mL vs 3.28 pg/mL;p=0.001)。
  • 糖尿病与GFAP水平呈负相关(β=-0.01;p<0.001)。

核心结论

  • 在双种族社区成人样本中,性别差异、慢性肾病和血管危险因素而非自报种族贡献了血浆AD生物标志物的变异。
  • 研究结果强调在普通人群中有效和公平地应用血浆AD生物标志物时,需要考量广泛的医学和社会健康决定因素。

研究设计与样本

  • 参与者通过梅奥诊所杰克逊维尔阿尔茨海默病研究中心评估,并按年龄、性别和认知状态匹配。
  • 样本包括非裔美国人(N=267)和非西班牙裔白人(N=268),69%为女性,年龄范围43-100岁(中位数80.2岁)。
  • 血浆AD生物标志物(Aβ42/40、p-tau181、GFAP和神经丝轻链)使用Quanterix SiMoA HD-X分析仪测量。
  • 认知采用简易精神状态检查评估,使用Wilcoxon秩和检验评估血浆生物标志物水平的性别差异,线性模型检验自报种族、慢性肾病和血管危险因素与血浆AD生物标志物水平的关联。

主要发现

  • 非裔美国人与非西班牙裔白人参与者之间血浆AD生物标志物水平无差异,按认知状态(未受损 vs 受损)分层后结果不变。
  • p-tau181与认知的关联似乎在白人参与者中更强,而Aβ42/40与认知的关联似乎在非裔美国人中更强,但排除慢性肾病患者后这些发现不再成立。
  • 女性参与者GFAP较高(177.5 pg/mL vs 157.73 pg/mL;p=0.002),p-tau181较低(2.62 pg/mL vs 3.28 pg/mL;p=0.001)。
  • 糖尿病与GFAP水平呈负相关(β=-0.01;p<0.001)。
  • 非西班牙裔白人教育程度较高(中位数16 vs 12年,p<0.001),非裔美国人APOE ε4阳性率较高(43% vs 34%;p=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Recent advances in blood-based biomarkers offer the potential to revolutionize the diagnosis and management of Alzheimer disease (AD), but additional research in diverse populations is critical. We assessed the profiles of blood-based AD biomarkers and their relationships to cognition and common medical comorbidities in a biracial cohort. METHODS: Participants were evaluated through the Mayo Clinic Jacksonville Alzheimer Disease Research Center and matched on age, sex, and cognitive status. Plasma AD biomarkers (β-amyloid peptide 1-42 [Aβ42/40], plasma tau phosphorylated at position 181 [p-tau181], glial fibrillary acidic protein [GFAP], and neurofilament light) were measured using the Quanterix SiMoA HD-X analyzer. Cognition was assessed with the Mini-Mental State Examination. Wilcoxon rank sum tests were used to assess for differences in plasma biomarker levels by sex. Linear models tested for associations of self-reported race, chronic kidney disease (CKD), and vascular risk factors with plasma AD biomarker levels. Additional models assessed for interactions between race and plasma biomarkers in predicting cognition. RESULTS: The sample comprised African American (AA; N = 267) and non-Hispanic White (NHW; N = 268) participants, including 69% female participants and age range 43-100 (median 80.2) years. Education was higher in NHW participants (median 16 vs 12 years, p < 0.001) while APOE ε4 positivity was higher in AA participants (43% vs 34%; p = 0.04). We observed no differences in plasma AD biomarker levels between AA and NHW participants. These results were unchanged after stratifying by cognitive status (unimpaired vs impaired). Although the p-tau181-cognition association seemed stronger in NHW participants while the Aβ42/40-cognition association seemed stronger in AA participants, these findings did not survive after excluding individuals with CKD. Female participants displayed higher GFAP (177.5 pg/mL vs 157.73 pg/mL; p = 0.002) and lower p-tau181 (2.62 pg/mL vs 3.28 pg/mL; p = 0.001) levels than male participants. Diabetes was inversely associated with GFAP levels (β = -0.01; p < 0.001). DISCUSSION: In a biracial community-based sample of adults, we observed that sex differences, CKD, and vascular risk factors, but not self-reported race, contributed to variation in plasma AD biomarkers. Although some prior studies have reported primary effects of race/ethnicity, our results reinforce the need to account for broad-based medical and social determinants of health (including sex, systemic comorbidities, and other factors) in effectively and equitably deploying plasma AD biomarkers in the general population.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ramanan VK, Graff-Radford J, Syrjanen J, et al. Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort. Neurology. 2023. PMID: 37580163. doi:10.1212/WNL.0000000000207675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。